AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel DiseasePRNewsWire • 06/13/24
AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/12/24
US Gastroenterologists Express Anticipation for Approval of AbbVie's Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-LaunchGlobeNewsWire • 06/12/24
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant RecipientsPRNewsWire • 06/11/24
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian CancerPRNewsWire • 06/06/24
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their CareersPRNewsWire • 06/06/24
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough PotentialInvestorPlace • 06/05/24
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383PRNewsWire • 06/05/24
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign SupremeInvestorPlace • 06/05/24
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic ArthritisPRNewsWire • 06/04/24
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50PRNewsWire • 06/04/24